Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome

by Bin Eshaq, Abdulhadi M , Jokhdar, Hani A.A , Assiri, Abdullah M , Sherbeeni, Nisreen M , Hayden, Frederick G , Al-Hameed, Fahad , Asiri, Ayed Y , Mandourah, Yasser , Fowler, Robert A , Memish, Ziad A , Jose, Jesna , AlMutairi, Badriah M , Deeb, Ahmad M , Al-Dawood, Abdulaziz , Al Faraj, Sarah , Bajhmom, Wail , Al Mekhlafi, Ghaleb A , Al Bshabshe, Ali , Ghazal, Sameeh , Arabi, Yaseen M , Abdelzaher, Mohamed , Hussein, Mohamed A , Elzein, Fatehi E , Azzam, Mohamed H.A , Balkhy, Hanan H , Alothman, Adel , Al Saedi, Asim , Alharbi, Naif K , Al Johani, Sameera , Al Harbi, Shmeylan , Al Jeraisy, Majed

in Administration, Oral / Adult / Aged / Antiretroviral drugs / Antiviral drugs / Coronavirus Infections - drug therapy / Coronavirus Infections - mortality / Coronaviruses / COVID-19 / Double-Blind Method / Drug Combinations / Drug Therapy, Combination / Female / Hospitalization / Humans / Injections, Subcutaneous / Interferon / Interferon beta-1b - adverse effects / Interferon beta-1b - therapeutic use / Kaplan-Meier Estimate / Lopinavir / Lopinavir - adverse effects / Lopinavir - therapeutic use / Male / Medical research / Middle Aged / Middle East respiratory syndrome / Mortality / Pandemics / Patients / Respiratory diseases / Ritonavir / Ritonavir - adverse effects / Ritonavir - therapeutic use / Statistics, Nonparametric / Time-to-Treatment

2020

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome

2020

Confirm

Do you wish to request the book?

Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome

2020

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome

Bin Eshaq, Abdulhadi M,

Jokhdar, Hani A.A,

Assiri, Abdullah M,

Sherbeeni, Nisreen M,

Hayden, Frederick G,

Al-Hameed, Fahad,

Asiri, Ayed Y,

Mandourah, Yasser,

Fowler, Robert A,

Memish, Ziad A,

Jose, Jesna,

AlMutairi, Badriah M,

Deeb, Ahmad M,

Al-Dawood, Abdulaziz,

Al Faraj, Sarah,

Bajhmom, Wail,

Al Mekhlafi, Ghaleb A,

Al Bshabshe, Ali,

Ghazal, Sameeh,

Arabi, Yaseen M,

Abdelzaher, Mohamed,

Hussein, Mohamed A,

Elzein, Fatehi E,

Azzam, Mohamed H.A,

Balkhy, Hanan H,

Alothman, Adel,

Al Saedi, Asim,

Alharbi, Naif K,

Al Johani, Sameera,

Al Harbi, Shmeylan,

Al Jeraisy, Majed

2020

Overview

In a double-blind, randomized, controlled trial, 95 patients with MERS in Saudi Arabia received recombinant interferon beta-1b plus lopinavir–ritonavir or placebo for 14 days. Active treatment led to improved survival at 90 days when initiated within 7 days after illness onset.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Administration, Oral

/ Adult

/ Aged

/ Antiretroviral drugs

/ Antiviral drugs

/ Coronavirus Infections - drug therapy

/ Coronavirus Infections - mortality